284 related articles for article (PubMed ID: 34048614)
1. Purpuric lesions on the eyelids developed after BNT162b2 mRNA COVID-19 vaccine: another piece of SARS-CoV-2 skin puzzle?
Mazzatenta C; Piccolo V; Pace G; Romano I; Argenziano G; Bassi A
J Eur Acad Dermatol Venereol; 2021 Sep; 35(9):e543-e545. PubMed ID: 34048614
[No Abstract] [Full Text] [Related]
2. Pigmented purpuric dermatosis after BNT162B2 mRNA COVID-19 vaccine administration.
Atak MF; Farabi B; Kalelioglu MB; Rao BK
J Cosmet Dermatol; 2022 Feb; 21(2):435-437. PubMed ID: 34791786
[No Abstract] [Full Text] [Related]
3. BNT162b2 mRNA COVID-19 vaccine-induced chilblain-like lesions reinforces the hypothesis of their relationship with SARS-CoV-2.
Piccolo V; Bassi A; Argenziano G; Mazzatenta C; Cutrone M; Neri I; Grimalt R; Russo T
J Eur Acad Dermatol Venereol; 2021 Aug; 35(8):e493-e494. PubMed ID: 33914966
[No Abstract] [Full Text] [Related]
4. Skin ulcer at the injection site of BNT162b2 mRNA COVID-19 vaccine.
Aoki N; Saruta Y; Tanaka S; Nakajima R; Sano H; Sano S
J Dermatol; 2021 Dec; 48(12):e596-e597. PubMed ID: 34545609
[No Abstract] [Full Text] [Related]
5. Cutaneous reaction to BNT162b2 mRNA COVID-19 vaccine.
López-Valle A; Falkenhain-López D; Arranz CR
Int J Dermatol; 2021 Jul; 60(7):891-892. PubMed ID: 33855706
[No Abstract] [Full Text] [Related]
6. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
[TBL] [Abstract][Full Text] [Related]
7. Dynamics of antibody response to BNT162b2 mRNA COVID-19 vaccine after 6 months.
Ponticelli D; Antonazzo IC; Caci G; Vitale A; Della Ragione G; Romano ML; Borrelli M; Schiavone B; Polosa R; Ferrara P
J Travel Med; 2021 Dec; 28(8):. PubMed ID: 34697627
[No Abstract] [Full Text] [Related]
8. BNT162B2 mRNA COVID-19 Vaccine in Heart and Lung Transplanted Young Adults: Is an Alternative SARS-CoV-2 Immune Response Surveillance Needed?
Cotugno N; Pighi C; Morrocchi E; Ruggiero A; Amodio D; Medri C; Colagrossi L; Russo C; Di Cesare S; Santilli V; Manno EC; Zangari P; Giancotta C; Bernardi S; Nicolosi L; Ciofi Degli Atti M; Raponi M; Zaffina S; Alfieri S; Kirk R; Perno CF; Rossi P; Amodeo A; Palma P
Transplantation; 2022 Feb; 106(2):e158-e160. PubMed ID: 34954734
[No Abstract] [Full Text] [Related]
9. Eosinophilic cellulitis after BNT162b2 mRNA Covid-19 vaccine.
de Montjoye L; Marot L; Baeck M
J Eur Acad Dermatol Venereol; 2022 Jan; 36(1):e26-e28. PubMed ID: 34547138
[No Abstract] [Full Text] [Related]
10. Safety and BNT162b2 mRNA COVID-19 vaccination.
Joob B; Wiwanitkit V
Acta Biomed; 2022 Jan; 92(6):e2021485. PubMed ID: 35075060
[TBL] [Abstract][Full Text] [Related]
11. BNT162b2 mRNA COVID-19 vaccine induces antibodies of broader cross-reactivity than natural infection, but recognition of mutant viruses is up to 10-fold reduced.
Chang X; Augusto GS; Liu X; Kündig TM; Vogel M; Mohsen MO; Bachmann MF
Allergy; 2021 Sep; 76(9):2895-2998. PubMed ID: 33948956
[No Abstract] [Full Text] [Related]
12. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Wang X
N Engl J Med; 2021 Apr; 384(16):1577-1578. PubMed ID: 33596350
[No Abstract] [Full Text] [Related]
13. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Vergnes JN
N Engl J Med; 2021 Apr; 384(16):1577. PubMed ID: 33596349
[No Abstract] [Full Text] [Related]
14. Anti-SARS-CoV-2 IgA Response in Baseline Seronegative and Seropositive Recipients of BNT162b2 mRNA COVID-19 Vaccine.
Salvagno GL; Henry BM; Lippi G
J Occup Environ Med; 2021 Nov; 63(11):e829. PubMed ID: 34412098
[No Abstract] [Full Text] [Related]
15. Vaccine-induced immune thrombotic thrombocytopenia after the BNT162b2 mRNA Covid-19 vaccine: A case study.
Rodríguez C; Pérez-Nieva A; Máiz L; Meijón MDM; Llamas P; Monreal M; Bikdeli B; Jiménez D
Thromb Res; 2021 Dec; 208():1-3. PubMed ID: 34649161
[No Abstract] [Full Text] [Related]
16. Ipsilateral herpes zoster after the first dose of BNT162b2 mRNA COVID-19 vaccine.
Tessas I; Kluger N
J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):e620-e622. PubMed ID: 34058038
[No Abstract] [Full Text] [Related]
17. Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab.
Altieri M; Capuano R; Conte M; Donnarumma G; Grimaldi E; Coppola N; Galdiero M; d'Ambrosio A; Tedeschi G; Gallo A
Neurol Sci; 2022 May; 43(5):2947-2949. PubMed ID: 35171373
[TBL] [Abstract][Full Text] [Related]
18. Monitoring of the immunogenic response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers with Snibe SARS-CoV-2 S-RBD IgG chemiluminescent immunoassay.
Salvagno GL; Henry BM; Pighi L; De Nitto S; Gianfilippi GL; Lippi G
Clin Chem Lab Med; 2021 Sep; 59(10):e377-e379. PubMed ID: 34162025
[No Abstract] [Full Text] [Related]
19. Re: Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine.
Mungmunpuntipantip R; Wiwanitkit V
Ultrasound Obstet Gynecol; 2021 Dec; 58(6):958. PubMed ID: 34855292
[No Abstract] [Full Text] [Related]
20. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
Beckley M; Olson AK; Portman MA
JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
